Inventor

BOON-FALLEUR THIERRY

BE142 patents

⚠️ This page may combine multiple inventors who share the name “BOON-FALLEUR THIERRY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BOON-FALLEUR THIERRY

LUDWIG INST CANCER RES

MAGE-A4 antigenic peptides and uses thereof

Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof

Leukemia associated genes

Method for screening for possible presence of cancer

Mage-3 peptides presented by HLA class II molecules

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof

Isolated peptides derived from tumor rejection antigens, and their use

Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Mage-3 peptides presented by HLA class II molecules

Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors

Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof

Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals

Isolated, tyrosinase derived peptides and uses thereof

Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof

Isolated, tyrosinase derived peptides and uses thereof

Tumor associated nucleic acids and uses therefor

MAGE-3 peptides presented by HLA class II molecules

Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof

Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof

Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof

Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof

Tumor antigens and CTL clones isolated by a novel procedure

Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4

Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

MAGE-A3 peptides presented by HLA class II molecules

Endogenous retrovirus tumor associated nucleic acids and antigens

Mage-A3 peptides presented by HLA class molecules

Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof

Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof

Leukemia associated genes

Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene products

MAGE peptides presented by HLA class II molecules

Isolated nucleic acid molecules which encode tumor rejection antigens found in dage

UNIV LEIDEN

Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

DEMOTTE NATHALIE

Method for modulating activity of T lymphocytes